With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
CAH — frequently asked questions
Is Cardinal Health, Inc. overvalued?
In our latest published analysis dated 2026-10-03, CAH looks modestly undervalued. The price recorded at analysis is USD 228 versus our fair value of USD 244; the high endpoint is presented separately as potential value of USD 320. That implies roughly 6.9% upside to fair value at that date.
Our latest published report, analyzed 2026-10-03, gives CAH a fair value of USD 244 and a potential value of USD 320. The conclusion is triangulated across multiple valuation models and weighted by reliability for Cardinal Health, Inc.'s archetype; it is a dated research output, not a live price.
Should I buy CAH now?
Our latest published rating for CAH, analyzed 2026-10-03, is Hold. Cardinal Health, Inc. looks modestly undervalued at the analysis-date price of USD 228 versus fair value of USD 244; potential value is USD 320. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for CAH?
The dedicated bear-case section in our report analyzed 2026-10-03 documents Cardinal Health, Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is CAH's rating?
Our latest published rating for CAH, analyzed 2026-10-03, is Hold, with a published moat assessment of 8/10 (Narrow). It reflects our fair value of USD 244, the potential value of USD 320, and the price recorded at analysis (USD 228).
Accelerated adoption of biosimilars and higher-margin specialty distribution solutions, paired with automated warehouse throughput efficiencies, expanding enterprise operating margin from 1.03% toward peer levels of 1.35%-1.42% seen at McKesson and Cencora, which would drive FY2028 diluted EPS toward the $14.90 consensus high and unlock fair value expansion toward $320.21.
Main risk
CVS Health contract renegotiation shock or volume loss cutting account contribution below 20% of consolidated revenue.
Cardinal Health Inc. (NYSE: CAH) is rated Hold with a composite intrinsic fair value of $244.05 compared to a current share price of $228.30 as of 2026-10-02, offering a modest 6.9% implied upside. While the business benefits from wholesale triopoly scale, a nearly 99% order fill rate, and robust $4.53B free cash flow, razor-thin 1.03% operating margins and anchor customer concentration with CVS Health (28% of revenue) warrant a neutral stance at current market levels.4,5,6,7,8
Customer and group purchasing organization (GPO) concentration represents the principal headwind to valuation expansion. CVS Health contributed 28% of consolidated FY2026 revenue, while sales under Vizient and Premier GPO agreements represented 29%. Given Cardinal Health's razor-thin consolidated operating margin of 1.03% ($2,613M operating profit on $254.25B revenue in FY2026),, contract pricing concessions or warehouse wage inflation could rapidly compress operating earnings. The defection of OptumRx in FY2024 (a 17% revenue contributor) demonstrates that customer losses are a recurring structural risk in drug wholesaling, corroborated by post-earnings FY2027 consensus revenue revisions falling by 3.91% to $265.86B.1,7,8
Cardinal Health's narrow economic moat (score 8.0) is underpinned by physical distribution density and ongoing automation investments that optimize logistics throughput. Enterprise service reliability achieved a nearly 99% order fill rate and record on-time departures in FY2026 without heavy capital intensity, as FY2026 capital expenditures totaled $649M (0.26% of revenue). The primary economic engine remains the Pharmaceutical and Specialty Solutions segment, which generated $234.83B in revenue (92.4% of total) and $2.78B in segment operating income. Disciplined working capital execution supported $5.17B in operating cash flow and $4.53B in free cash flow, enabling management to reduce diluted shares outstanding to 237M.4
Valuation models indicate that Cardinal Health is fairly valued. The composite intrinsic fair value of $244.05 indicates a 6.9% implied upside from the October 2, 2026 closing price of $228.30, corresponding to a 6.5% discount to intrinsic value. This composite fair value sits 2.8% below the present-value equivalent ($251.07) of the analyst consensus 12-month price target ($270.33 undiscounted, discounted 1.0 year at a 7.67% cost of equity). Trading at 17.7x forward earnings, Cardinal Health trades at a comparable multiple to wholesale peer McKesson (17.90x forward P/E) and a modest premium to Cencora (15.59x forward P/E). With risk-adjusted return bounded below the 10% buy threshold, existing positions should be held.2
Indispensable Wholesale Triopoly Distribution Scale
Cardinal Health, McKesson, and Cencora control over 90% of U.S. pharmaceutical wholesale distribution. Duplicating Cardinal Health's daily temperature-controlled logistics infrastructure is economically prohibitive, securing enterprise fill rates near 99% across $234.83B in Pharmaceutical and Specialty Solutions revenue.5,8
Cardinal Health, Inc. provides pharmaceuticals and medical products and cost-effective services and solutions that enhance the healthcare system and supply chain efficiency. Cardinal Health, Inc. connects patients, providers, payers, pharmacists, and manufacturers for integrated care coordination.
Its at-Home Solutions operating segment includes two main businesses: a direct-to-patient provider business that includes
A rigorous stress test evaluates the vulnerability of Cardinal Health's razor-thin 1.03% operating margin ($2,613M operating income on $254.25B revenue in FY2026), to joint volume and pricing shocks. Customer concentration is acute: anchor pharmacy partner CVS Health generates 28% of revenue ($71.19B), while GPOs Vizient and Premier represent 29% ($73.73B). Precedent exists for major customer attrition, as evidenced by the departure of OptumRx in FY2024, which eliminated 17% of consolidated revenue. Under a stress scenario where CVS Health extracts a 10 bps fee concession and reallocates 20% of its volume, combined with 4% distribution center wage inflation and $3.3B in debt maturities refinancing into a 5.24% risk-free rate environment, consolidated operating margin compresses to 0.80%. Annual operating profit drops below $2.1B, cutting net income and driving diluted EPS toward $13.15 by FY2028, illustrating the sharp operating deleverage inherent in high-volume, low-margin wholesale distribution.
Cardinal Health derives its competitive advantage from operating as an indispensable physical logistics backbone of the U.S. healthcare system. In fiscal 2026, the company generated $254.25B in consolidated revenue, distributing pharmaceuticals and medical supplies to healthcare providers across the country. Operating alongside McKesson and Cencora, Cardinal Health benefits from an entrenched wholesale triopoly that commands more than 90% of domestic drug distribution volume. This market concentration creates significant efficient scale, as the vast inventory requirements, specialized cold-chain infrastructure, and daily delivery schedules create high barriers to entry for prospective competitors.
The company's primary moat source is its route density and warehouse automation scale. In FY2026, capital expenditures were maintained at a disciplined $649M, representing approximately 0.26% of revenue, while continuous automation expansion drove total fill rates to nearly 99% and achieved historical records for on-time departures. Management has systematically eliminated operational bottlenecks to lower handling costs per unit, enabling Cardinal Health to profitably process hundreds of billions of dollars in pharmaceutical volume on an enterprise operating margin of 1.03% ($2,613M ).
The highlighted cell is Fair value when every assumption sits at its base level ($244.05). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $1.9B after modeled reinvestment of $263.6M, with terminal value at 83.2% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Upgrade the rating; Re-examine the durability of operating margin expansion, verify whether working capital tailwinds contributed to cash flow, and assess specialty pharmaceutical mix expansion before adjusting portfolio allocation.
Trigger: Consolidated quarterly operating income showing sustained acceleration, with Pharmaceutical segment operating margin expanding above baseline and CVS Health contract renewal confirmed on favorable terms.
A decisive beat driven by accelerating specialty pharmaceutical distribution and warehouse automation savings would demonstrate structural operating leverage beyond historical baseline, closing the gap with peer operating margins and justifying an upgrade.
Cardinal Health maintained capital expenditures of $649M in FY2026 (~0.26% of revenue) while depreciation and amortization stood at $956M, resulting in negative net capex of -$307M. Multiyear automation investments are targeted directly at resolving distribution bottlenecks rather than speculative capacity overbuilding.5,7
Bull cycle
In an expansionary wholesale distribution cycle, accelerating adoption of specialty pharmaceuticals, biosimilars, and GLP-1 therapies drives volume growth across provider networks. Multiyear warehouse automation investments yield operational leverage, expanding consolidated operating margins from 1.03% toward peer levels of 1.35%-1.42% seen at McKesson and Cencora, while working capital efficiency accelerates generation.
§11 Position management
Sizing
3-5%
Cardinal Health is an established mature compounder trading at $228.30 as of October 2, 2026, representing a modest 6.5% discount to compositefair value of 244.05. A moderate position weighting of 3-5% reflects its stable wholesale oligopoly position and robust cash conversion ($4.53B FCF in FY2026), balanced against significant revenue concentration with CVS Health (28%) and thin 1.03% operating margins that limit near-term upside re-rating.4,6,7,8
§12 Investor perspectives
Institutional / Total Return Compounder
Hold
Cardinal Health generates steady single-digit revenue growth ($254.25B in FY2026) and strong operating cash flow ($5.17B), supporting durable per-share compounding through buybacks. However, with fair value at $244.05 and forward P/E at 17.7x, market pricing adequately reflects operating execution, warranting holding existing allocations.4,7
Income and Dividend Growth Investor
Hold
The company supports a regular dividend of $2.06 per share backed by $4.53B in free cash flow and 237M shares outstanding. Although dividend safety is high, prioritizes share repurchases over yield expansion, positioning CAH as a capital-preservation hold rather than an income-maximizing asset.
§14 Final recommendation
Action
Hold
Maintain a Hold rating on Cardinal Health Inc. (CAH). The stock trades at $228.30 as of 2026-10-02 against a composite intrinsic fair value of $244.05, offering 6.9% implied upside and a 6.5% discount to intrinsic value. At 17.7x forward earnings, the shares adequately reflect current distribution volume momentum, triopoly stability, and strong free cash flow ($4.53B in FY2026), while leaving an insufficient margin of safety for the 28% customer concentration with CVS Health.4,6
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Specialty Distribution and Biosimilar Mix Enrichment
Continued expansion across higher-margin specialty pharmaceutical distribution, downstream provider solutions, and biosimilars is projected to expand consolidated operating margins from 1.03% in FY2026 toward peer levels of 1.25%-1.35% by FY2031.5,7
Customer concentration headwinds materialize as contract renegotiation pressure from CVS Health or GPOs Vizient and Premier forces fee concessions, echoing the volume loss seen with OptumRx in FY2024. On a thin operating margin buffer, distribution center wage inflation and higher debt refinancing rates compress operating profit, dropping diluted EPS toward the low end of consensus expectations in FY2028 and pushing valuation to the lower band.
Ways this thesis can break
Growth stagnation and valuation multiple de-rating under healthcare distribution reform
Current forward P/E is 17.7x, with a house terminal P/E modeled at 15.5x. If regulatory drug pricing reforms, such as expanded Medicare price negotiation under the Inflation Reduction Act, and customer pricing concessions compress distribution economics, multiple contraction toward peer medical device and specialty levels of 12.49x, would reduce equity fair value by 20% or more.3,4,5
FV impact
-4.7%
Terminal multiple 20% lower
Trigger
Within 24 months
Early-warning signals to monitor
The five developments that would weaken our investment case.
Indicates customer volume diversion, contract non-renewal, or partial self-distribution by CVS Health, collapsing distribution route density and causing severe operating deleverage on thin distributor margins.
Signals severe distributor fee compression or distribution center wage and freight inflation exceeding automation savings, reducing annual operating profit below $2.1B.
Loss of health system member volume or aggressive fee discounting during GPO contract renegotiations, eroding Pharmaceutical and Specialty Solutions profit contribution.
Despite these formidable operational advantages, Cardinal Health's economic moat is rated Narrow rather than Wide due to extreme customer and intermediary concentration. Sales to anchor retail client CVS Health accounted for 28% of total revenue in FY2026, while sales through GPOs Vizient and Premier represented 29%. The historical loss of OptumRx in FY2024, which previously contributed 17% of revenue, confirms that large customers possess substantial bargaining leverage during contract renegotiations. This counter-leverage caps fee margins, bounding the firm's economic moat durability to a 10-year horizon (5 years explicit Stage I, 5 years Stage II fade).
Cardinal Health generates extraordinary accounting return on invested capital of 42.36%, significantly exceeding its computed WACC of 7.16% and cost of equity of 7.67%. This high economic profit spread reflects low capital intensity ($649M capex on $254.25B revenue,) and negative invested capital dynamics arising from working capital float and cumulative share buybacks. However, because operating margin is ultra-thin at 1.03%, economic profit is bounded by customer bargaining power, affirming a Narrow rather than Wide moat rating.2,7
8/ 10
Narrow
Sources of advantage
01Cost Advantage and Automated Logistics Scale — Cardinal Health manages an expansive physical infrastructure of regional distribution centers and automated fulfillment facilities supporting $254.25B in FY2026 revenue on modest capex of $649M (~0.26% of revenue). Targeted warehouse automation resolves fulfillment bottlenecks and lowers handling cost per order, achieving an enterprise fill rate of nearly 99% and record on-time departures that cannot be replicated without prohibitive capital expenditure.Wide
02Efficient Scale within Wholesale Triopoly — The U.S. wholesale drug distribution sector is an entrenched oligopoly where Cardinal Health, McKesson, and Cencora distribute over 90% of all pharmaceuticals. This market structure is characterized by rational pricing and clustered operating margins (Cardinal Health at 1.03%, McKesson at 1.35%, and Cencora at 1.42%). Thin operating margins and massive revenue scale act as a formidable barrier to potential entrants, ensuring sustainable economic volume across core distribution corridors.Wide
03High Switching Costs in Hospital and Pharmacy Networks — Long-term contractual relationships with GPOs Vizient and Premier (29% of FY2026 revenue) and retail anchor CVS Health (28% of FY2026 revenue) embed Cardinal Health directly into customer inventory workflows, ordering software, and daily clinical dispensing. Switching distributors introduces severe operational risk and supply continuity disruption, although historical customer defection (OptumRx in FY2024) caps switching costs at moderate strength.Moderate
Contract renegotiation pressure or volume loss from CVS Health (28% of revenue)
high
1-3 years
Deep workflow and IT integration with CVS retail pharmacies, multiyear contract structures, and the prohibitive capital cost for CVS to self-distribute ambient and cold-chain pharmaceuticals nationwide.
Fee compression during periodic contract renewals with major GPOs Vizient and Premier (29% of revenue)
medium
1-2 years
Credit risk is diversified across thousands of individual hospital members rather than concentrated at the GPO level, while expanding specialty distribution and biosimilar offerings preserves aggregate fee margins.8
Distribution center wage inflation and transportation cost escalation on thin 1.03% operating margins
medium
Ongoing / 12-24 months
Accelerating deployment of automated sorting and robotic picking to drive down handling cost per order on disciplined capital outlays ($649M capex in FY2026).5,7
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Cardinal Health executes steadily within the wholesale triopoly, expanding operating margins gradually from FY2026 through FY2027 and FY2028 toward terminal targets by FY2031. Revenue advances from reported FY2026 baseline through FY2027 and FY2028 consensus paths, while diluted EPS expands above reported historical levels through forward expectations, supported by ongoing share repurchases. This yields the compositeFair value of $244.05.1,7
Revenue growth accelerates supported by specialty pharmaceutical demand
Diluted EPS achieves the high end of consensus expectations by FY2028
Net share count reduction sustained at an accelerated pace annually
Consolidated operating margin expands toward peer levels matching McKesson and closing the gap with Cencora, driven by distribution automation efficiencies and specialty pharmaceutical mix growth. With strong cash generation sustaining share repurchases, diluted EPS reaches the upper tier of consensus expectations and fair value expands toward $320.21.1,5
In-line
Maintain Hold; Preserve existing position weighting, verify execution milestones across distribution automation initiatives, and monitor customer concentration metrics at the next quarterly checkpoint.
Trigger: Quarterly revenue and diluted EPS matching post-event consensus estimates, with steady distribution volume across core health system and retail pharmacy accounts.
In-line results confirm the mature compounder thesis of predictable revenue growth, steady free cash generation, and disciplined share repurchases, keeping valuation closely aligned with Fair value of $244.05.
Miss
Downgrade the rating; Assess contract retention risk with CVS Health and GPO partners, evaluate distribution center cost inflation, and consider reducing position size to limit capital exposure.
Trigger: Quarterly operating margin contracting below historical baseline, operating income deteriorating due to cost inflation, or disclosure of customer volume attrition from CVS Health.
A material earnings miss would signal that distribution labor and freight inflation are outpacing automation efficiencies or that major customer fee compression is taking hold, eroding the thin operating margin buffer and jeopardizing forward EPS targets across FY2027 and FY2028.
CurrentStable proportion of consolidated revenue in FY2026, remaining consistent with historical range.
Why it matters
CVS Health represents a substantial share of total revenue; any change in contract terms or volume insourcing directly impacts distribution route density and operating profit.
Cash flow generation in FY2026 was robust, driven by operating cash flow of $5,174M and free cash flow of $4,525M, converting at more than 2.6x reported GAAP net income of $1,714M. Favorable working capital timing contributed to this cash flow performance; the house valuation model prudently normalizes future reinvestment rates to 12% of NOPAT in FY2027-FY2028 and 10% thereafter. Stock-based compensation of $367M in FY2026 represents corporate overhead that partially offsets automation labor efficiencies, fully reflected in the net share count forecast.6,7
Capital allocation demonstrates disciplined compounder governance. With FY2026 operating cash flow reaching $5,174M, management allocated $649M to capex (~0.26% of revenue) focused on warehouse automation, distributed $491M in dividends ($2.06 per share), and deployed $1.36B to share repurchases. Balance sheet cash stands at $4,856M, providing substantial liquidity to manage scheduled debt maturities ($1.88B within one year, $3.30B within three years out of $9,948M total debt) in an elevated interest rate environment (risk-free rate 5.24%).
High ROIC is an outcome of low capital intensity ($649M capex on $254.25B revenue,) combined with negative accounting equity resulting from cumulative share repurchases. While high return on capital confirms excellent capital efficiency, the thin 1.03% operating margin leaves cash flow sensitive to customer contract renegotiations.
Economic ROIC of 42.36% substantially exceeds computed WACC of 7.16% and cost of equity of 7.67%, indicating strong economic value creation.
Pharmaceutical and Specialty Solutions is the Sole Profit Driver
Consolidated revenue reached $254.25B in FY2026, with Pharmaceutical and Specialty Solutions contributing $234.83B (92.4% of total) and $2,783M in segment operating income.
Enterprise financial performance and earnings growth are overwhelmingly driven by core drug distribution volume and specialty mix, making non-pharma operations secondary to valuation.
Low Capital Intensity Supports Exceptional Free Cash Flow Conversion
Wholesale distribution scale requires minimal incremental capex to grow, enabling Cardinal Health to convert operating profit into substantial free cash flow for capital returns.
Consistent Share Repurchases Power Per-Share Compounding
Diluted shares outstanding declined from 242M in FY2025 to 237M in FY2026, continuing a multiyear reduction from 279M in FY2022.
A projected -1.40% annual share count reduction amplifies modest 4.5%-6.2% top-line growth into mid-to-high single-digit EPS accretion net of $367M SBCdilution.
Cardinal Health Inc. (CAH) trades at 17.7x forward earnings against a peer median of 16.7x. Its EV/EBITDA of 13.8x compares with a peer median of 14.6x. The comparison uses 4 peers: Cencora Inc., McKesson Corporation, Agilent Technologies Inc. and Boston Scientific Corporation, as of 2026-10-03.
In a distribution downcycle, regulatory pricing interventions such as Inflation Reduction Act drug price negotiations lower wholesale invoice values, while retail pharmacy network distress prompts customer contract renegotiations or store closures. Simultaneously, distribution center wage and freight inflation outpaces automated efficiency gains, compressing operating margins below 0.80% and causing sharp profit contraction.
Secular trends
Trend
Impact
Note
Specialty Pharmaceutical and Biosimilar Mix Expansion
positive
Rapid volume growth in complex biologic, oncology, and specialty therapies requires specialized cold-chain handling, driving favorable fee mix within Pharmaceutical and Specialty Solutions ($234.83B revenue in FY2026).
Healthcare Supply Chain Automation and Robotics Integration
positive
Deployment of automated sorting systems and robotics across distribution centers mitigates warehouse labor inflation and enhances order accuracy, driving total fill rate to nearly 99%.
Legislative Drug Pricing Scrutiny and PBM Realignment
neutral
The Inflation Reduction Act introduces manufacturer price negotiation and WACC adjustments, but distributor fee-for-service models insulate wholesale cash flow from direct drug price deflation.
Retail Pharmacy Network Rationalization
negative
Store closures and reimbursement pressure across retail pharmacy chains like CVS Health (28% of revenue) exert continuous margin pressure on wholesale distribution contracts.
Positioning
Cardinal Health holds an indispensable position within the U.S. pharmaceutical supply chain oligopoly. With $254.25B in FY2026 revenue and deeply entrenched relationships with GPOs Vizient and Premier (29% of revenue) and CVS Health (28% of revenue), the company's daily fulfillment network is insulated from new entrants. However, its thin 1.03% operating margin leaves it more exposed to client defection than direct peers McKesson and Cencora.7,8
Risk
Risk management centers on mitigating customer concentration exposure and operating leverage vulnerability. Given the heavy revenue concentration with CVS Health (28% of revenue) and thin 1.03% operating margins, portfolio exposure should be capped at 5% of equity. Refinancing risk on $3.3B of debt maturing over the next three years is closely monitored, though mitigated by $4.86B in cash and strong annual operating cash flow ($5,174M in FY2026). Positions should be rebalanced whenever market prices approach compositefair value ($244.05).
Entry tranches
Level
Action
Why
$225 - $230 (Baseline trading corridor)
Maintain existing allocation / Hold
Shares trade near compositefair value of 244.05 (6.9% implied upside). Existing holdings should be maintained rather than aggressively expanded.
Approaches the forward earnings conservative model anchor ($190.47), offering asymmetric risk/reward assuming core CVS Health and GPO volumes remain stable.
Operating as a member of an indispensable three-firm drug distribution oligopoly, Cardinal Health provides non-cyclical demand stability, supported by an adjusted beta of 0.5876. High customer concentration with CVS Health (28% of revenue) and $9.95B total debt balance this defensive profile, supporting a disciplined Hold.2,4,8
Investors should maintain current holdings rather than deploying incremental capital. Cardinal Health functions as an indispensable logistics utility with reliable share repurchase accretion (diluted shares reduced to 237M), but enterprise upside is constrained by anchor customer bargaining leverage and thin 1.03% operating margins. A more compelling entry point would require a price discount toward $200-$210 or verifiable acceleration of specialty distribution operating margins toward 1.25%.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Discounted forecast-period cash flows ($42.71) plus discounted terminal value ($212) minus signed net debt per current share ($21.99) equals the $233 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
